search
Back to results

User Performance and System Accuracy Evaluations Using Glucose Adjustment

Primary Purpose

Type 1 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Blood Glucose Monitoring Systems.
Sponsored by
LifeScan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 1 Diabetes Mellitus

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesDoes not accept healthy volunteers

Summary of inclusion criteria.

  • Male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 months and treated with a basal bolus insulin regime, and deemed otherwise healthy as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening.
  • Non-smokers from at least 12 months before study start and for the duration of the study.
  • Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.
  • Able to voluntarily provide written informed consent to participate in the study.
  • Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
  • Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
  • The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study.
  • User Performance Accuracy Testing Only: Self-Monitoring - Volunteer is currently performing unassisted self-monitoring of blood glucose.

Summary of exclusion criteria.

  • A severe hypoglycaemic reaction, defined as causing loss of consciousness and/or requiring outside assistance with oral or intravenous glucose or a glucagon injection, within 7 days of the study start date.
  • Female volunteers who are pregnant or lactating.
  • Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  • Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
  • Participation in a clinical drug study during the 90 days prior to study start.
  • Any clinically significant illness within 30 days prior to study start.
  • Donation of blood or blood products within 30 days prior to study start, or at any time during the study, except as required by this protocol.
  • Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males.
  • Consumption of alcoholic beverages within 48 hours prior to check-in.
  • Volunteers with a substantial change in eating habits within 30 days prior to study start or volunteers who cannot comply with the standardised meals proposed for use in the study.
  • Prior experience with the BGMSs used for the study.
  • Volunteers who are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets blood glucose monitoring products.
  • Volunteers who have laboratory training or experience (medical technologist, laboratory technician, laboratory assistant etc).
  • Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.

Sites / Locations

  • BioKinetic Europe Ltd

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Blood Glucose monitoring System (BGMS)

Arm Description

Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)

Outcomes

Primary Outcome Measures

User Performance (UP) evaluation.
UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by subject and HCP
System Accuracy (SA) evaluation
UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by HCP only.

Secondary Outcome Measures

Full Information

First Posted
February 18, 2015
Last Updated
August 14, 2017
Sponsor
LifeScan
search

1. Study Identification

Unique Protocol Identification Number
NCT02374879
Brief Title
User Performance and System Accuracy Evaluations Using Glucose Adjustment
Official Title
User Performance and System Accuracy Evaluations Using Glucose Adjustment
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
February 1, 2015 (Actual)
Primary Completion Date
February 1, 2015 (Actual)
Study Completion Date
February 1, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LifeScan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment. Twelve male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 will be enrolled in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Blood Glucose monitoring System (BGMS)
Arm Type
Experimental
Arm Description
Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
Intervention Type
Device
Intervention Name(s)
Blood Glucose Monitoring Systems.
Intervention Description
In vitro diagnostic medical device.
Primary Outcome Measure Information:
Title
User Performance (UP) evaluation.
Description
UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by subject and HCP
Time Frame
Up to 6 hours
Title
System Accuracy (SA) evaluation
Description
UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by HCP only.
Time Frame
Up to 6 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Summary of inclusion criteria. Male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 months and treated with a basal bolus insulin regime, and deemed otherwise healthy as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening. Non-smokers from at least 12 months before study start and for the duration of the study. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2. Able to voluntarily provide written informed consent to participate in the study. Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process. Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS). The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study. User Performance Accuracy Testing Only: Self-Monitoring - Volunteer is currently performing unassisted self-monitoring of blood glucose. Summary of exclusion criteria. A severe hypoglycaemic reaction, defined as causing loss of consciousness and/or requiring outside assistance with oral or intravenous glucose or a glucagon injection, within 7 days of the study start date. Female volunteers who are pregnant or lactating. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in. Participation in a clinical drug study during the 90 days prior to study start. Any clinically significant illness within 30 days prior to study start. Donation of blood or blood products within 30 days prior to study start, or at any time during the study, except as required by this protocol. Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males. Consumption of alcoholic beverages within 48 hours prior to check-in. Volunteers with a substantial change in eating habits within 30 days prior to study start or volunteers who cannot comply with the standardised meals proposed for use in the study. Prior experience with the BGMSs used for the study. Volunteers who are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets blood glucose monitoring products. Volunteers who have laboratory training or experience (medical technologist, laboratory technician, laboratory assistant etc). Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David J Bell
Organizational Affiliation
BioKinetic Europe Ltd
Official's Role
Principal Investigator
Facility Information:
Facility Name
BioKinetic Europe Ltd
City
Belfast
State/Province
Antrim
ZIP/Postal Code
BT2 7BA
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

User Performance and System Accuracy Evaluations Using Glucose Adjustment

We'll reach out to this number within 24 hrs